Results
The study was conducted between September 14, 2018, and June 12, 2020. A total of 154 participants were screened for eligibility and 70 (mean [SD] age, 47.6 [10.7] years; 52 [74%] female and 18 [26%] male) were randomized: 35 to liraglutide, 3.0 mg, once daily plus lifestyle intervention and 35 to placebo plus lifestyle intervention (